Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Dr. Scagliotti on the Future of Multiple Gene Profiles

October 12th 2011

Dr. Giorgio Scagliotti from the University of Turin Discusses the Future of Multiple Gene Profiles

Dr. Tripathy Discusses Iniparib Trial Heterogeneity

October 11th 2011

Dr. Debu Tripathy from USC Norris Comprehensive Cancer Center Discusses Iniparib Trial Heterogeneity

Efforts to Improve HER2 Testing Continue ASCO Panelist Sees Progress

October 11th 2011

Improving the accuracy and value of tumor marker testing in patients with breast cancer has resulted in a dramatic upswing in accredited laboratories and the clarification of guideline definitions.

The Complexities of Inhibiting Angiogenesis Emerge

October 10th 2011

During the past 40 years, the concept of thwarting a tumor by attacking its blood supply has become a central thrust of cancer research, a strategy that reached a milestone with the approval of bevacizumab in 2004.

Dr. Scagliotti on Mechanisms of Resistance to EGFR TKIs

October 7th 2011

Dr. Giorgio V. Scagliotti from the University of Turin on Mechanisms of Resistance to EGFR TKIs

Dr. Mills on the Development of Combination Therapies

October 7th 2011

Dr. Gordon B. Mills from MD Anderson Cancer Center Discusses the Development of Combination Therapies

Research Interest in Bevacizumab Remains Robust

October 6th 2011

Despite controversy over its breast cancer approval status, bevacizumab (Avastin) remains at center stage when it comes to antiangiogenic therapies for the disease.

Dr. Langer Discusses the JMEN Maintenance Pemetrexed Trial

October 6th 2011

Dr. Corey J. Langer from Abramson Cancer Center Discusses the JMEN Maintenance Pemetrexed Trial

Dr. McDonald on the Continued Understanding of Bevacizumab

October 6th 2011

Dr. Donald McDonald from the UCSF Comprehensive Cancer Center on the Continued Understanding of Bevacizumab

A Look Into the Future of Breast Cancer: A Conversation With Joyce A. O'Shaughnessy, MD

October 6th 2011

Leading breast cancer researcher Joyce A. O'Shaughnessy, MD, developed and chaired the 10th International Congress on the Future of Breast Cancer, a 4-day interactive program.

5 Questions for Nita Maihle, PhD

October 5th 2011

Nita Maihle, PhD, is a professor of Obstetrics, Gynecology and Reproductive Sciences, and director of a clinically oriented cancer research laboratory at Yale University, New Haven, Connecticut.

Dr. Rugo on Proliferation as an Anti-Angiogenesis Marker

October 5th 2011

Dr. Hope S. Rugo from University of California, San Francisco on Proliferation as an Anti-Angiogenesis Marker

When Less Is More: An Interview With J. Michael Dixon, MBChB, MD

October 5th 2011

Professor of Surgery and Consultant Surgeon at the University of Edinburgh; and Clinical Director of the Edinburgh Breast Unit at the Western General Hospital in Edinburgh, Scotland.

Dr. Langer on Assessing Patient Populations in Trials

October 4th 2011

Dr. Corey J. Langer from Abramson Cancer Center on Assessing Patient Populations in Clinical Trials

Making a Mark in Lung Cancer: An Interview With Roy S. Herbst, MD, PhD

October 4th 2011

Roy S. Herbst, MD, PhD, is a physician and translational researcher, whose work in developing novel, personalized therapies for lung cancer has helped drive significant changes in the way the disease is treated.

Oncogenic Signaling of the EGFR: Familiar Target Faces New Questions

October 3rd 2011

The epidermal growth factor receptor (EGFR) is the prototypical receptor tyrosine kinase (RTK) and one of the most comprehensively studied molecular targets in clinical oncology.

Dr. Mills Explains the Vulnerability of Cancer Cells

October 3rd 2011

Dr. Gordon Mills from MD Anderson Cancer Center Explains the Vulnerability of Cancer Cells

Dr. Morrow Describes the ACOSOG Z11 Trial

September 30th 2011

Dr. Monica Morrow from Memorial Sloan-Kettering Cancer Center Describes the ACOSOG Z11 Trial

Dr. Wakelee on Adjuvant Therapy Predictive Markers

September 30th 2011

Dr. Heather Wakelee from Stanford Clinical Cancer Center Discusses Adjuvant Therapy Predictive Markers

Dr. Mills on the Shifts Towards Personalized Medicine

September 29th 2011

Dr. Gordon B. Mills from MD Anderson Cancer Center Discusses Shifts Towards Personalized Medicine